OCUL
Ocular Therapeutix Inc
NASDAQ: OCUL · HEALTHCARE · BIOTECHNOLOGY
$9.21
-1.18% today
Updated 2026-04-29
Market cap
$2.00B
P/E ratio
—
P/S ratio
38.59x
EPS (TTM)
$-1.42
Dividend yield
—
52W range
$6 – $16
Volume
4.9M
Ocular Therapeutix Inc (OCUL) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10000.00 | — | $772000.00 | $1.75M | $1.89M | $1.92M | $1.99M | $4.23M | $17.40M | $43.52M | $51.49M | $58.44M | $63.72M | $51.82M |
| Revenue growth (YoY) | — | -100.0% | — | +126.7% | +7.8% | +1.9% | +3.5% | +112.4% | +311.7% | +150.1% | +18.3% | +13.5% | +9.0% | -18.7% |
| Cost of revenue | $7000.00 | $10.52M | $91000.00 | $319000.00 | $443000.00 | $457000.00 | $465000.00 | $2.33M | $2.08M | $4.41M | $4.54M | $5.28M | $5.63M | $6.57M |
| Gross profit | $3000.00 | $-10.52M | $681000.00 | $1.43M | $1.44M | $1.47M | $1.52M | $1.90M | $15.32M | $39.12M | $46.95M | $53.16M | $58.10M | $45.25M |
| Gross margin | 30.0% | — | 88.2% | 81.8% | 76.5% | 76.2% | 76.6% | 45.0% | 88.0% | 89.9% | 91.2% | 91.0% | 91.2% | 87.3% |
| R&D | $11.54M | $10.52M | $18.88M | $26.61M | $27.07M | $30.88M | $36.91M | $41.09M | $28.69M | $50.08M | $53.46M | $61.05M | $127.64M | $197.10M |
| SG&A | $1.48M | $1.76M | $6.91M | $9.16M | $11.00M | $15.51M | $18.79M | $22.12M | $22.86M | $31.88M | $67.98M | $33.94M | $60.65M | $64.38M |
| Operating income | $-13.67M | $-12.90M | $-27.09M | $-38.20M | $-43.33M | $-61.92M | $-59.12M | $-85.80M | $-62.85M | $-78.04M | $-78.65M | $-82.38M | $-171.78M | $-270.02M |
| Operating margin | -136710.0% | — | -3509.6% | -2182.7% | -2296.0% | -3220.1% | -2970.8% | -2029.9% | -361.1% | -179.3% | -152.7% | -141.0% | -269.6% | -521.0% |
| EBITDA | $-13.31M | $-12.50M | $-26.98M | $-37.27M | $-42.14M | $-59.87M | $-55.95M | $-77.74M | $-146.09M | $2.54M | $-61.91M | $-66.42M | $-176.14M | $-249.78M |
| EBITDA margin | -133120.0% | — | -3495.1% | -2129.7% | -2233.3% | -3113.3% | -2811.7% | -1839.2% | -839.5% | 5.8% | -120.2% | -113.6% | -276.4% | -482.0% |
| EBIT | $-13.72M | $-12.90M | $-27.53M | $-38.02M | $-43.02M | $-61.49M | $-58.24M | $-80.27M | $-148.87M | $118000.00 | $-64.02M | $-69.40M | $-179.93M | $-254.10M |
| Interest expense | $377000.00 | $441000.00 | $1.12M | $1.72M | $1.68M | $1.89M | $1.74M | $6.10M | $6.77M | $6.67M | $7.02M | $11.34M | $13.58M | $11.84M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-14.09M | $-13.32M | $-28.65M | $-39.75M | $-44.70M | $-63.39M | $-57.69M | $-86.37M | $-155.64M | $-6.55M | $-71.04M | $-80.74M | $-193.51M | $-265.94M |
| Net income growth (YoY) | — | +5.5% | -115.1% | -38.7% | -12.5% | -41.8% | +9.0% | -49.7% | -80.2% | +95.8% | -984.1% | -13.7% | -139.7% | -37.4% |
| Profit margin | -140930.0% | — | -3710.9% | -2271.3% | -2369.0% | -3296.2% | -2899.1% | -2043.3% | -894.3% | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% |